Bone Biologics CORP 10-Q quarterly reports

Bone Biologics Corporation's Q2 2026 Form 10-Q highlights ongoing net losses and a substantial accumulated deficit, raising concerns about its ability to continue as a going concern despite recent capital raises.

Bone Biologics Corporation reported a net loss of $765,988 for Q1 2026, with a significant decrease in research and development expenses, while general and administrative costs rose.

Bone Biologics Corporation reported a narrower net loss and increased cash reserves for Q3 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Bone Biologics Corporation reported increased cash reserves and progress in its clinical trials, despite continued net losses and ongoing going concern doubts.

Bone Biologics Corporation announced its Q1 2025 financial results, highlighting increased research and development spending and addressing a Nasdaq deficiency notice regarding its minimum bid price.

Bone Biologics Corporation announced its third quarter 2024 financial results, highlighting a decrease in research and development expenses and the commencement of a pilot clinical study for its NB1 bone graft device.

Bone Biologics Corporation announced its second quarter 2024 financial results, highlighting a decrease in operating expenses and the commencement of a pilot clinical study for its NB1 bone graft device.

Bone Biologics Corporation reported its financial results for the first quarter of 2024, showing a significant decrease in research and development expenses and a net loss of $865,970.